Literature DB >> 14871804

Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions.

Sangyeul Han1, Túlio M Santos, Ana Puga, Jenn Roy, Elizabeth A Thiele, Mia McCollin, Anat Stemmer-Rachamimov, Vijaya Ramesh.   

Abstract

Tuberous sclerosis complex is caused by mutations in tumor suppressor genes TSC1 or TSC2 and is characterized by the presence of hamartomas in many organs. Although tuberous sclerosis complex is a tumor suppressor gene syndrome with classic "second hits" detectable in renal tumors, conventional genetic analysis has not revealed somatic inactivation of the second allele in the majority of human brain lesions. We demonstrate a novel mechanism of post-translational inactivation of the TSC2 protein, tuberin, by physiologically inappropriate phosphorylation, which is specific to tuberous sclerosis complex-associated brain lesions. Additional analysis shows that tissue specificity is due to abnormal activation of the Akt and mitogen-activated protein kinase pathways in brain but not in renal tumors. These results have widespread implications for understanding the tissue specificity of tumor suppressor gene phenotypes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871804     DOI: 10.1158/0008-5472.can-03-3277

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway.

Authors:  Jaroslaw Jozwiak; Sergiusz Jozwiak; Tomasz Grzela; Maciej Lazarczyk
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 2.  The tuberous sclerosis complex.

Authors:  Ksenia A Orlova; Peter B Crino
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

Review 3.  Epilepsy related to developmental tumors and malformations of cortical development.

Authors:  Eleonora Aronica; Peter B Crino
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 4.  Somatic mutation, genomic variation, and neurological disease.

Authors:  Annapurna Poduri; Gilad D Evrony; Xuyu Cai; Christopher A Walsh
Journal:  Science       Date:  2013-07-05       Impact factor: 47.728

5.  Ornithine decarboxylase, the rate-limiting enzyme of polyamine synthesis, modifies brain pathology in a mouse model of tuberous sclerosis complex.

Authors:  David Kapfhamer; James McKenna; Caroline J Yoon; Tracy Murray-Stewart; Robert A Casero; Michael J Gambello
Journal:  Hum Mol Genet       Date:  2020-08-11       Impact factor: 6.150

6.  Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas.

Authors:  Sangyeul Han; Carolyn Polizzano; Gunnlaugur P Nielsen; Francis J Hornicek; Andrew E Rosenberg; Vijaya Ramesh
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

7.  NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.

Authors:  Marianne F James; Sangyeul Han; Carolyn Polizzano; Scott R Plotkin; Brendan D Manning; Anat O Stemmer-Rachamimov; James F Gusella; Vijaya Ramesh
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

8.  Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.

Authors:  Philippe P Roux; Bryan A Ballif; Rana Anjum; Steven P Gygi; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

Review 9.  Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.

Authors:  Vera P Krymskaya
Journal:  Proc Am Thorac Soc       Date:  2008-01-01

10.  Genetics and molecular biology of tuberous sclerosis complex.

Authors:  Valerio Napolioni; Paolo Curatolo
Journal:  Curr Genomics       Date:  2008-11       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.